ThinkCyte, a biotechnology company specializing in innovative single-cell analysis and sorting solutions, has successfully raised $32 million in its Series C funding round. This includes an additional $15 million from an extension round, bringing the company’s total funding to $91 million. The latest round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. 7 Investment Limited Partnership, with additional support from Japan Finance Corporation.
The funds will be used to scale up production and manufacturing and accelerate the global commercial expansion of ThinkCyte’s flagship product, VisionSort™. Launched in June 2023, VisionSort™ is the world’s first AI-based, dual-mode fluorescence and morphometric cell sorting platform. It has already been adopted by major biopharmaceutical companies and academic institutions worldwide.
ThinkCyte, founded in 2016 with offices in Tokyo and Redwood City, California, develops multidisciplinary scientific instruments that support life science research, diagnostics, and therapeutic development. The company aims to further its impact in the life sciences by driving advancements through its cutting-edge technologies and expanding its global footprint.
